Podcast appearances and mentions of Johnson Johnson

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

Regulations governing AI are more than likely on their way – but a lot of unknowns remain. Some might say too many unknowns remain, which isn't great for business. While clear, comprehensive regulations for AI are widely expected – and requested – by nearly every sector of the economy, there's plenty we don't know.  That said, business leaders can not and will not operate in the dark.  Executives in our orbit, whether leading drug manufacturers, major medical marketing agencies or health media companies, require at least a sense of what's on the horizon. This week, pharma editor Lecia Bushak speaks with Darshan Kulkarni, a pharma regulatory consultant and founding partner at his namesake law firm. Their conversation explores the potential of new laws and regulations around AI use cases in medical marketing, such as digital avatars. And for our Trends segment, we're talking about Bayer's lawsuit against Johnson & Johnson for its marketing practices around a prostate cancer drug. Plus, we are graced with a dramatic reading of Steve Madden's satirical FDA Untitled Letter to ESPN over their faux pharma ad for March Madness.   Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until February 22, 2027.Immune Innovation in Head and Neck Cancer: Insights on Checkpoint Inhibitors and Bispecifics Across Disease Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bicara Therapeutics Inc., Coherus BioSciences, Inc., Johnson & Johnson, and Merus.Disclosure information is available at the beginning of the video presentation.

Measuring AI marketing ROI has become one of the most uncomfortable conversations in tech and marketing teams. Everyone knows AI is "important." Fewer teams can explain what success actually looks like. Even fewer can tie adoption to real outcomes rather than experimentation for its own sake. For developers and technical leaders, this isn't a tooling problem — it's a decision-making problem. The teams that win are the ones that slow down just enough to define value before they ship. About Meeky Hwang Meeky Hwang's journey resonates with entrepreneurs, technical leaders, and anyone navigating the intersection of technology and business. As CEO and Co-Founder of Ndevr, a digital solutions development agency, Meeky brings over 20 years of experience building resilient, scalable platforms for organizations including Johnson & Johnson, Pfizer, Forbes, PMC, and Bloomberg. Her work goes beyond website development—she focuses on long-term digital solutions that improve performance, streamline workflows, and align technology with business strategy. Equally important is Meeky's perspective as a woman leading in a male-dominated industry. She has navigated the challenges of technical leadership, entrepreneurship, and scaling a services business while building credibility and strong teams along the way. Her experience offers an honest look at what it takes to grow as a leader without losing sight of innovation, people, or purpose. Follow on LinkedIn and her Website. Measuring AI marketing ROI when the hype is louder than the data AI adoption today often starts with pressure instead of purpose. Tools arrive before goals. Budgets get approved before success criteria exist. That's the first red flag. If you can't articulate what improvement AI is supposed to create — conversion lift, content velocity, operational savings, personalization accuracy — you're not measuring ROI. You're chasing momentum. Measuring AI marketing ROI by defining outcomes before tools The most effective teams reverse the typical process. They define outcomes first, then ask which capabilities might support those outcomes. That discipline alone filters out most bad investments. Before selecting tools, answer three questions: What problem are we solving? How will we measure improvement? What happens if this fails? If those answers feel vague, that's your signal to pause. Measuring AI marketing ROI with clear baselines and success metrics ROI requires comparison. Without a baseline, every result looks impressive — or disappointing — depending on expectations. Establish: A pre-AI performance baseline A specific success threshold A review window short enough to stop bad bets early This turns AI from a belief system into an experiment with guardrails. Measuring AI marketing ROI without wasting budget on "maybe" features Not every feature deserves implementation just because it exists. Time and money are always the real constraints. Teams that succeed evaluate AI features the same way they evaluate architecture decisions: cost, risk, effort, and impact. When those tradeoffs are visible, priorities clarify quickly. Measuring AI marketing ROI while Google, SEO, and platforms keep shifting AI doesn't exist in isolation. SEO changes, platform updates, and algorithm shifts constantly reshape the playing field. That makes flexibility more valuable than novelty. Incremental improvements that survive change often outperform bold implementations that lock teams into fragile solutions. Measuring AI marketing ROI alongside compliance requirements and regional rules Global websites introduce real constraints — privacy, consent, accessibility, and regulatory differences. AI features that ignore compliance increase risk faster than they increase value. Measuring AI marketing ROI with a repeatable compliance checklist A checklist-driven approach ensures new features don't break trust or regulation: Regional consent and privacy rules Accessibility requirements Data handling expectations This protects ROI by preventing costly rework. Measuring AI marketing ROI through discovery, QA, UAT, and launch checklists Strong discovery reduces downstream chaos. Structured QA and UAT validate assumptions. Launch checklists prevent avoidable mistakes. AI doesn't replace these fundamentals — it amplifies their importance. Measuring AI marketing ROI as a founder: delegate, stay lean, and still scale Technical founders often delay hiring because they can do the work themselves. That works — until it doesn't. Sustainable ROI requires delegation. Growth depends on trusting others to execute while leaders focus on direction, not tickets. Callout: AI ROI Scorecard Define outcomes, baselines, and review windows before implementation Decide early whether to pilot, pause, or proceed Callout: Website Launch Checklist (Minimum Viable) QA, UAT, accessibility, and responsiveness checks Hosting, CDN, and integration validation Callout: Delegation Rules for Technical Founders Decide what you keep vs. hand off Train once, so execution scales later Conclusion Measuring AI marketing ROI isn't about skepticism — it's about clarity. When teams define value first, use disciplined checklists, and resist hype-driven decisions, AI becomes a multiplier instead of a distraction. If you want better outcomes, start with better questions — and build from there. Stay Connected: Join the Developreneur Community We invite you to join our community and share your coding journey with us. Whether you're a seasoned developer or just starting, there's always room to learn and grow together. Contact us at info@develpreneur.com with your questions, feedback, or suggestions for future episodes. Together, let's continue exploring the exciting world of software development. Additional Resources Online Communities and Marketing Creating your Marketing Site Branding and Marketing Fundamentals with Kevin Adelsberger Develpreneur - Forward Momentum Podcast Videos – With Bonus Content

Investigative journalist Gardiner Harris joins us to talk about No More Tears: The Dark Secrets of Johnson & Johnson, an explosive expose of an organization whose image as a ""child-friendly" baby company" contrasts against "reams of evidence showing decades of deceitful and dangerous corporate practices that have threatened the lives of millions."

The Developer to CEO transition rarely starts with a bold declaration like, "I'm going to run a company." More often, it begins quietly—by taking on one more responsibility, saying yes to a new opportunity, or stepping into a role that stretches just a little beyond your comfort zone. In this episode of the Building Better Developers podcast, part of our Forward Momentum season, we talk with Meeky Hwang about how that transition unfolds in real life. Her path—from developer to agency founder and CEO—reflects a pattern many experienced engineers recognize only in hindsight. Over time, those small decisions add up. You stop thinking only about code and start thinking about people, clients, sustainability, and direction. At some point, you realize you're no longer just building software—you're building a business. About Meeky Hwang Meeky Hwang's journey resonates with entrepreneurs, technical leaders, and anyone navigating the intersection of technology and business. As CEO and Co-Founder of Ndevr, a digital solutions development agency, Meeky brings over 20 years of experience building resilient, scalable platforms for organizations including Johnson & Johnson, Pfizer, Forbes, PMC, and Bloomberg. Her work goes beyond website development—she focuses on long-term digital solutions that improve performance, streamline workflows, and align technology with business strategy. Equally important is Meeky's perspective as a woman leading in a male-dominated industry. She has navigated the challenges of technical leadership, entrepreneurship, and scaling a services business while building credibility and strong teams along the way. Her experience offers an honest look at what it takes to grow as a leader without losing sight of innovation, people, or purpose. Follow on LinkedIn and her Website. Developer to CEO transition starts with "accidental" opportunities For many engineers, this transition begins almost by accident. A consulting role exposes you to different industries. A startup forces you to wear multiple hats. An agency environment teaches you how delivery, relationships, and trust intersect. None of these roles comes with a "future CEO" label. But they do build instincts—how to prioritize, how to adapt, and how to make tradeoffs when perfect solutions aren't possible. Those instincts matter far more than a perfectly mapped career plan. Developer to CEO transition lessons from consulting, startups, and agencies Each environment contributes something different to the Developer to CEO transition. Consulting sharpens communication and expectation-setting. Startups teach ownership and resilience. Agencies reveal what it takes to scale work without burning people out. Individually, these roles can feel chaotic. Together, they form a foundation that prepares developers for leadership long before they realize that's where they're headed. Developer to CEO transition and the mindset shift to full responsibility There's a moment in the transition when responsibility feels heavier. Decisions don't stop at your team or your sprint—they ripple outward. Hiring, pricing, client relationships, and long-term viability all land on your plate. Problems are no longer theoretical. They're personal. This shift changes how leaders think. It forces clarity, prioritization, and the ability to move forward without perfect information. Developer to CEO transition accelerators: mastermind and founder groups One of the most impactful accelerators in the Developer to CEO transition is joining founder communities earlier than you think you need them. Mastermind ROI for New Owners Real conversations about hiring, benefits, pricing, and mistakes Exposure to how other founders actually run their businesses Founder groups shorten the learning curve by replacing isolation with shared experience. Instead of guessing, you learn from people who've already been there. Developer to CEO transition accountability: learning faster through peers Accountability is often underestimated in the Developer to CEO transition. Founder groups create a rhythm of progress—not through pressure, but through shared momentum. The "Accidental" Path That Works Follow opportunities that increase learning, not just status Optimize early for exposure and experience, not polish When you know you'll report back to peers who care, progress stops being optional. Developer to CEO transition when your role forces personal growth The Developer to CEO transition also reshapes how leaders show up. Many founders start as quiet contributors, comfortable behind the scenes. Leadership changes that. Mindset Shifts in the Developer to CEO transition Responsibility changes how decisions feel—and how quickly they must be made Visibility and communication become part of the job Growth here isn't about changing who you are. It's about growing into what the role requires. Developer to CEO transition and evolving the agency niche over time As companies mature, the Developer to CEO transition continues through strategic evolution. Niches tighten, then expand. Focus shifts based on market feedback, strengths, and timing. The most successful agencies don't chase trends. They adjust deliberately, guided by experience rather than impulse. Developer to CEO transition: what to do earlier if you could restart Ask founders what they'd change, and many give the same answer: find peer support sooner. The Developer to CEO transition becomes clearer—and far less lonely—when you're not navigating it in isolation. This episode of the Building Better Developers podcast is a reminder that growth doesn't come from having all the answers. It comes from asking better questions, learning from others, and building momentum—one decision at a time. Stay Connected: Join the Developreneur Community We invite you to join our community and share your coding journey with us. Whether you're a seasoned developer or just starting, there's always room to learn and grow together. Contact us at info@develpreneur.com with your questions, feedback, or suggestions for future episodes. Together, let's continue exploring the exciting world of software development. Additional Resources Maintaining Momentum And Steady Progress Consistency And Momentum: Keys To Success New Year, New Momentum: What Developers Can Look Forward to in 2026 Habits, Roadmaps, and the Value of Career Momentum Building Better Foundations Podcast Videos – With Bonus Content

Lorraine Marchand, startup CEO, advisor to Johnson & Johnson, member of the Pharmaceutical Advisory Board at Columbia Business School, and faculty at Wharton, discusses how leaders can sustain growth through disciplined experimentation in an era shaped by AI and institutional risk aversion.  Marchand's perspective is grounded in a career that spans large corporations and entrepreneurial ventures. Early in life, she learned to treat problem solving as an experiment rather than a test of personal worth. That principle later informed her approach to innovation in complex organizations. Several practical themes emerge from the discussion: 1. Reframe failure as structured learning. Marchand's operating principle is "try, fail, learn." The key is to set explicit learning objectives before undertaking a new initiative. When leaders define what they intend to learn, not just what they intend to achieve, they reduce fear and increase resilience. This mindset is particularly critical in startups and new ventures, where there is no playbook and early missteps are inevitable. 2. Innovation requires protected investment. Drawing on research and executive interviews, Marchand highlights the value of disciplined portfolio allocation. A 70/20/10 model—70% core business, 20% adjacent opportunities, 10% new, exploratory ideas—creates room for experimentation without destabilizing the enterprise. The evidence she cites suggests that long-term growth frequently emerges from ideas that initially seemed peripheral. 3. Culture often suppresses experimentation. Organizations frequently default to "playing it safe." Marchand argues that leaders must explicitly create space for candor and reflection. Her practice of "Fail Free Friday", a structured forum to discuss what is not working without defensiveness, illustrates how small rituals can normalize learning and surface risk before it compounds. 4. AI should assist thinking, not replace it. Marchand observes both curiosity and fatigue around AI. Students and executives alike risk over-reliance, which can erode depth of analysis. Her discipline is simple: think independently first, then use AI as a research assistant to refine or challenge one's reasoning. Senior leaders remain relevant not by competing with automation, but by asking the right questions, an ability rooted in experience and judgment. 5. Integration of technology requires business judgment. Technology cannot be bolted onto processes indiscriminately. Leaders must understand workflows deeply enough to decide where automation adds value, where human ingenuity remains essential, and where both are required. This integration demands clarity about the business, not just familiarity with the tool. 6. The "who" and the "how" matter more than the "what." Late-career reflection led Marchand to conclude that outcomes achieved at the expense of people erode long-term value. Values alignment, integrity, and disciplined focus, often expressed through the willingness to say no, are strategic decisions, not personal preferences. For senior professionals, the message is direct: sustained growth depends less on bold rhetoric and more on creating disciplined environments where experimentation is safe, technology is used thoughtfully, and people are encouraged to think independently. The capacity to ask better questions, protect time for reflection, and allocate resources to uncertain but promising ideas remains a defining leadership advantage. Lorraine H. Marchand, an acclaimed author and innovator, is author of the new book NO FEAR, NO FAILURE and a leading consultant and educator on innovation with deep expertise in new product development. She has cofounded multiple start-ups, held senior roles at global companies including Bristol-Myers Squibb, Covance/LabCorp, and IBM, and advises top organizations while teaching at the Wharton School and Yeshiva University. Get Lorraine's book, No Fear, No Failure, here: https://tinyurl.com/eksdu9ks Claim your free gift: Free gift #1 McKinsey & BCG winning resume www.FIRMSconsulting.com/resumePDF Free gift #2 Breakthrough Decisions Guide with 25 AI Prompts www.FIRMSconsulting.com/decisions Free gift #3 Five Reasons Why People Ignore Somebody www.FIRMSconsulting.com/owntheroom Free gift #4 Access episode 1 from Build a Consulting Firm, Level 1 www.FIRMSconsulting.com/build Free gift #5 The Overall Approach used in well-managed strategy studies www.FIRMSconsulting.com/OverallApproach Free gift #6 Get a copy of Nine Leaders in Action, a book we co-authored with some of our clients: www.FIRMSconsulting.com/gift

President Trump says he'll decide whether to attack Iran in the next 10 days, Johnson & Johnson is reportedly considering selling its orthopedics unit, Amazon's AI tools sparked two outages at the company's cloud unit, according to the FT, Live Nation reported strong live concert demand, and President Trump will direct the release of files on “extraterrestrial life.” Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CBS lawyers shut down Stephen Colbert's Senate interview — and suddenly it's “Trump censorship.” A Democrat Super PAC darkens Jasmine Crockett's skin in a primary ad. A DHS building is targeted in Idaho. And the New England Journal of Medicine quietly admits COVID vaccine blood clots were real. Tara connects the dots on media double standards, political hypocrisy, terror labeling, and the slow unraveling of the COVID narrative.

From CBS equal-time chaos to Democrat ad racism, Idaho terror attempts, and COVID clot cover-ups — today's episode dives into everything the mainstream media downplays. Plus, U.S. military spending in Europe and Ukraine is under fire as hidden truths emerge about billions wasted, nuclear risks, and base access blocked by allies. Tara connects the dots on political double standards, media hypocrisy, and the slow unraveling of official COVID narratives.

Host: Rick Grobbee Guest: Annemien van den Bosch Want to watch that extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2552 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson

Changing regulations are reshaping the practice of oncology. Issues such as prior authorization, shifting coverage policies, reporting mandates, and reimbursement certainty all affect how clinics must operate to provide the best care. In this episode, CANCER BUZZ speaks with 3 oncology professionals, representing different roles and regions of the country, about their experiences of how policy impacts care delivery. Martin Palmeri, MD, MBA, FASCO, medical oncologist at Messino Cancer Centers, Patricia Serna, MHS, PA-C, CGRA, APP area manager at Texas Oncology, and Gretchen Van Dyck, financial counselor at Green Bay Oncology, connect the dots between legislative intents and clinical realities. "When my patients see that their options for clinical trials are diminishing, or some of these clinical trials are shutting down, they lose hope." - Martin Palmeri, MD, MBA, FASCO "Being able to work with the Texas Society of Clinical Oncology has given me that behind-the-scenes background of if we don't speak up, our patients are going to suffer." Patricia Serna, MHS, PA-C, CGRA Guests: Patricia Serna, MHS, PA-C, CGRA  APP Area Manager – APP Services Texas Oncology Dallas, TX Gretchen Van Dyck Financial Counselor II Green Bay Oncology Green Bay, WI  Martin Palmeri, MD, MBA, FASCO  Medical Oncologist Messino Cancer Centers Asheville, NC This podcast is part of the Oncology State Societies (OSS) Advocacy Engagement program, made possible with support from Johnson & Johnson. Resources: ACCC Advocacy Resources Access, Payment & Reimbursement Reform ACCC Community Oncology Research Institute (ACORI)  

Grâce à une fiscalité avantageuse, l'Irlande a su attirer les géants pharmaceutiques, au point d'en faire l'un des piliers de son économie. Mais Donald Trump brandit désormais la menace de droits de douane, pour pousser ces entreprises à relocaliser aux Etats-Unis. Or, les médicaments représentent près de la moitié des exportations irlandaises, avec les États-Unis comme premier client ! En Europe, l'Irlande serait ainsi le pays le plus exposé. Près de Cork, Ringaskiddy, surnommé le « village du Viagra », retient son souffle. Reportage de Clémence Pénard. John n'avait que 22 ans quand Pfizer s'est installé à Ringaskiddy. C'était en 1969 : « Tu vois, juste là, le château d'eau ? L'espèce de champignon, là ! Ça appartient à Pfizer !  » Le succès est tel que l'entreprise s'empresse de construire deux autres usines. Si bien qu'aujourd'hui, sous les coups de 8 heures, le site devient une véritable fourmilière : « Le matin, les routes sont totalement saturées : les files de voitures s'étendent sur des kilomètres. Et c'est la même chose le soir ! Une autoroute devait être construite il y a trente ans… Bon, elle doit être terminée d'ici trois ans. On vit dans l'espoir ! » Le « Pfizer Stop » Un arrêt de bus, le « Pfizer Stop », a tout de même été créé, rien que pour les salariés qui produisent, depuis 1998, le médicament le plus tonique de la région : le viagra !  « À l'époque, on n'arrivait même pas à prononcer le nom : "Pf i zeur" ! Mais tout le monde voulait y travailler, absolument tout le monde. Les salaires étaient multipliés par quatre ! Même le fournisseur de papier toilette était devenu riche ! » Et il n'a pas fallu longtemps pour que le « village du Viagra » attire d'autres géants pharmaceutiques. Aujourd'hui, les Américains Johnson & Johnson, Thermo Fisher ou encore BioMarin profitent eux aussi du port de cet ancien village de pêcheurs, idéal pour exporter leurs médicaments !  Et à seulement 20 km de là, Lilly fabrique Mounjaro et Zepbound, deux médicaments anti-obésité, best-sellers aux États-Unis !  Ambiance à Ringaskiddy et dans les villages voisins Ainsi, dans Ringaskiddy et les villages voisins, ce sont plus de 20 000 personnes qui travaillent pour ces mastodontes, souvent de génération en génération. Audrey Buckley est élue locale du Fianna Fáil, le parti au pouvoir : « S'il arrivait quoi que ce soit à l'industrie pharmaceutique ici, ce serait tout simplement dévastateur pour toute la région. Dévastateur… Aujourd'hui, au dîner autour de la table, les mêmes questions reviennent sans cesse : est-ce que tels travaux ont démarré à l'usine? Est-ce qu'il y a de nouveaux projets ? Or, tout semble à l'arrêt. C'est une énorme source d'angoisse, les gens repoussent l'achat d'une voiture, l'extension de la maison, et ainsi de suite. Ils dépensent moins, c'est sûr, donc on voit déjà des effets ! »  Économiste à l'université de Cork, Eleanor Doyle voit aussi un ralentissement du secteur, mais tente tout de même de rassurer : « Pour les usines pharmaceutiques, les délais pour obtenir les autorisations de construction sont si longs, qu'à moyen terme, une délocalisation est peu envisageable ! » Pour l'instant, l'Irlande profite d'un répit, l'administration américaine semblant se concentrer sur d'autres régions du monde.

Host: Emer Joyce Guest: Borge Nordestgaard Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2548 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Lp(a) and aortic valve stenosis The truth about climate change and heart disease Snapshots Host: Emer Joyce Guests: JP Carpenter, Borge Nordestgaard, Hugh Montgomery, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2548 Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1.  Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Hugh Montgomery has declared to have potential conflicts of interest to report: funded and runs the charity-funded non-profit 'Real Zero'. Unpaid co-chair of the UK Health Alliance on Climate Change, Lancet Countdown on Health and Climate Change. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode, investigative journalist Gardner Harris discusses his book 'No More Tears,' which exposes the dark secrets of Johnson & Johnson. He reveals the company's history of fraud, including the baby powder scandal, the deadly EPO drug, and the antipsychotic Risperdal. Harris emphasizes the role of whistleblowers in uncovering these truths and calls for significant reforms in drug regulation to prevent future tragedies.Fraud in America is made possible by the generous donation of Getnick Law, a boutique Manhattan law firm dedicated to fighting fraud and promoting business integrity.------------------Fraud in America Social Links

"One of our most unique and precious things we can use is our own voice." -Tina Dietz   Tina Dietz is an award-winning vocal leadership expert and founder and CEO of Twin Flames Studios, a premier audio publishing company helping entrepreneurs and experts turn their voices into powerful audiobooks and professionally published books. A pioneer in voice-powered publishing, she led the industry's first fully guided remote audiobook recording experience and is known for transforming podcast content into lasting authority and revenue-generating assets. With over 20 years of experience across 30+ industries and eight countries, Tina has worked with global brands including Johnson & Johnson, GE, Aetna, and UGG. Recognized by Forbes and Inc., and a founding member of the Forbes Coaches Council, she is a trusted voice shaping the future of audio publishing. Website: https://twinflamesstudios.com  LinkedIn: https://www.linkedin.com/in/tinadietz/  YouTube: https://www.youtube.com/@TwinFlamesStudios  Instagram: https://www.instagram.com/twinflamesstudios/  Facebook: https://www.facebook.com/TwinFlamesStudiosLeadership/    Zachary Bernard is the founder of We Feature You PR, a public relations company that helps individuals and businesses establish themselves as thought leaders through podcasts and press.  Since its inception, We Feature You PR has worked with 350+ clients, from solopreneurs to publicly traded companies, securing features in major publications like Forbes, Entrepreneur, and USA Today, and booking over a 1,000 podcast appearances. Website: https://wefeatureyou.com LinkedIn: https://www.linkedin.com/in/itszachb/ YouTube: https://www.youtube.com/@itszachb_ Instagram: https://www.instagram.com/itszachb_   In this episode, we explore leadership, podcast marketing, audiobook creation, and authentic AI strategies with Tina and Zach.    Apply to join our marketing mastermind group: https://notypicalmoments.typeform.com/to/hWLDNgjz   Follow No Typical Moments at: Website: https://notypicalmoments.com/ LinkedIn: https://www.linkedin.com/company/no-typical-moments-llc/ YouTube: https://www.youtube.com/channel/UC4G7csw9j7zpjdASvpMzqUA Instagram: https://www.instagram.com/notypicalmoments Facebook: https://www.facebook.com/NTMoments  

"One of our most unique and precious things we can use is our own voice." -Tina Dietz   Tina Dietz is an award-winning vocal leadership expert and founder and CEO of Twin Flames Studios, a premier audio publishing company helping entrepreneurs and experts turn their voices into powerful audiobooks and professionally published books. A pioneer in voice-powered publishing, she led the industry's first fully guided remote audiobook recording experience and is known for transforming podcast content into lasting authority and revenue-generating assets. With over 20 years of experience across 30+ industries and eight countries, Tina has worked with global brands including Johnson & Johnson, GE, Aetna, and UGG. Recognized by Forbes and Inc., and a founding member of the Forbes Coaches Council, she is a trusted voice shaping the future of audio publishing. Website: https://twinflamesstudios.com  LinkedIn: https://www.linkedin.com/in/tinadietz/  YouTube: https://www.youtube.com/@TwinFlamesStudios  Instagram: https://www.instagram.com/twinflamesstudios/  Facebook: https://www.facebook.com/TwinFlamesStudiosLeadership/    Zachary Bernard is the founder of We Feature You PR, a public relations company that helps individuals and businesses establish themselves as thought leaders through podcasts and press.  Since its inception, We Feature You PR has worked with 350+ clients, from solopreneurs to publicly traded companies, securing features in major publications like Forbes, Entrepreneur, and USA Today, and booking over a 1,000 podcast appearances. Website: https://wefeatureyou.com LinkedIn: https://www.linkedin.com/in/itszachb/ YouTube: https://www.youtube.com/@itszachb_ Instagram: https://www.instagram.com/itszachb_   In this episode, we explore leadership, podcast marketing, audiobook creation, and authentic AI strategies with Tina and Zach.    Apply to join our marketing mastermind group: https://notypicalmoments.typeform.com/to/hWLDNgjz   Follow No Typical Moments at: Website: https://notypicalmoments.com/ LinkedIn: https://www.linkedin.com/company/no-typical-moments-llc/ YouTube: https://www.youtube.com/channel/UC4G7csw9j7zpjdASvpMzqUA Instagram: https://www.instagram.com/notypicalmoments Facebook: https://www.facebook.com/NTMoments  

In this episode of Dividend Talk, we break down fresh warnings, dividend hikes, and the big stories in EuropeDividend growth investors need to understand right now.We start with the first earnings of the season, led by Johnson & Johnson, and dig into what its latest results tell us about dividend reliability, pipeline strength, and long-term growth. From there, we cover Fastenal and a mini dive into why its business model may be far more durable than “nuts and bolts” suggests, plus a closer look at the Swedish powerhouse Investor AB and its long-term compounding track record.Along the way, we also discuss:Recent dividend hikes from Essity, Tryg, Investor AB, L3Harris, and Valero EnergyWhether Europe's proposed wealth and unrealised gains taxes threaten long-term compoundingWhat Davos, Ray Dalio, gold, and shifting globalpower structures mean for dividend investorsThe role of gold, Bitcoin, and defensive assets in adividend-focused portfolioETF-based global dividend strategies vs.individual stock selectionHow we personally size positions and manageportfolio riskWhether owning highly profitable dividend payersraises ethical questionsListener Q&A on SaaS stocks, Evolution AB,airports, and portfolio construction

Dr. Jim Loehr is a world-renowned performance psychologist, whose ground-breaking, science-based energy management training system has achieved worldwide recognition. He has authored 17 books and worked with hundreds of world-class performers from the arenas of sport, business, medicine and law enforcement, including Fortune 100 executives, FBI Hostage Rescue Teams, and military Special Forces. Dr. Loehr has worked with hundreds of elite sports clients including 17 number ones in the world in their respective sports, multiple clients from professional tennis, golf, basketball, football, hockey, boxing, race car driving and the Olympics. Dr. Loehr is also the retired chairman, CEO, and co-founder of the Human Performance Institute (HPI), prior to its acquisition by Johnson & Johnson.  HPI is the pioneer in training programs designed to successfully leverage the science of energy management to improve the productivity and engagement levels of elite performers from the world of business, sport, medicine, and law enforcement, for sustained high performance. Dr. Haley Perlus (@drhaleyperlus) is a Performance Psychology expert, speaker, and author specializing in helping business leaders, entrepreneurs, and high achievers apply the mental strategies of elite athletes to reach peak performance. With a Ph.D. in Sport Psychology and certifications in coaching, fitness, and nutrition, she transforms high-stress environments into arenas for success. She is the author of Personal Podium: How to Use Your Mind to Maximize Your Potential, which distills the psychological strategies of world-class performers into practical techniques for business and personal growth. In our conversation today, we touch on many incredible topics including the importance of gratitude, coaching our inner voice, the Hidden Scorecard, and so much more. Jim and Haley share many practical tips and incredible stories from their their work with athletes and teams. Get ready to take some notes and likely listen to this one twice! Connect with Jim: https://www.jim-loehr.com/ Connect with Haley: https://drhaleyperlus.com/ BOOK A SPEAKER: Interested in having John or one of our speaking team come to your school, club or coaching event? We are booking November and December 2025 and Winter/Spring 2026 events, please email us to set up an introductory call John@ChangingTheGameProject.com PUT IN YOUR BULK BOOK ORDERS FOR OUR BESTSELLING BOOKS, AND JOIN 2025 CHAMPIONSHIP TEAMS FROM SYRACUSE MENS LAX, UNC AND NAVY WOMENS LAX, AND MCLAREN F1! These are just the most recent championship teams using THE CHAMPION TEAMMATE book with their athletes and support teams. Many of these coaches are also getting THE CHAMPION SPORTS PARENT so their team parents can be part of a successful culture. Schools and clubs are using EVERY MOMENT MATTERS for staff development and book clubs. Are you?  We have been fulfilling numerous bulk orders for some of the top high school and collegiate sports programs in the country, will your team be next? Click here to visit John's author page on Amazon Click here to visit Jerry's author page on Amazon Please email John@ChangingTheGameProject.com if you want discounted pricing on 10 or more books on any of our books. Thanks everyone. This week's podcast is brought to you by our friends at Sprocket Sports.  Sprocket Sports is a new software platform for youth sports clubs.  Yeah, there are a lot of these systems out there, but Sprocket provides the full enchilada. They give you all the cool front-end stuff to make your club look good– like websites and marketing tools – AND all the back-end transactions and services to run your business better so you can focus on what really matters – your players and your teams. Sprocket is built for those clubs looking to thrive, not just survive, in the competitive world of youth sports clubs.  So if you've been looking for a true business partner – not just another app – check them out today at https://sprocketsports.me/CTG. BECOME A PREMIUM MEMBER OF CHANGING THE GAME PROJECT TO SUPPORT THE PODCAST If you or your club/school is looking for all of our best content, from online courses to blog posts to interviews organized for coaches, parents and athletes, then become a premium member of Changing the Game Project today. For over a decade we have been creating materials to help change the game. and it has become a bit overwhelming to find old podcasts, blog posts and more. Now, we have organized it all for you, with areas for coaches, parents and even athletes to find materials to help compete better, and put some more play back in playing ball. Clubs please email John@ChangingTheGameProject.com for pricing.  Become a Podcast Champion! This weeks podcast is also sponsored by our Patreon Podcast Champions. Help Support the Podcast and get FREE access to our Premium Membership, with well over $1000 of courses and materials. If you love the podcast, we would love for you to become a Podcast Champion, (https://www.patreon.com/wayofchampions) for as little as a cup of coffee per month (OK, its a Venti Mocha), to help us up the ante and provide even better interviews, better sound, and an overall enhanced experience. Plus, as a $10 per month Podcast Super-Champion, you will be granted a Premium Changing the Game Project Membership, where you will have access to every course, interview and blog post we have created organized by topic from coaches to parents to athletes. Thank you for all your support these past eight years, and a special big thank you to all of you who become part of our inner circle, our patrons, who will enable us to take our podcast to the next level. https://www.patreon.com/wayofchampions

This episode covers: Cardiology This Week: A concise summary of recent studies What´s new in TAVI?  Digital solutions in arrhythmias Mythbusters - Gratitude is heart healthy Host: Emer Joyce Guests: JP Carpenter, Davide Capodanno, Fleur Tjong Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Want to watch that extended interview on Digital solutions in arrhythmias, go to: https://esc365.escardio.org/event/2528?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Host: Emer Joyce Guest: Fleur Tjong Want to watch that extended interview on https://esc365.escardio.org/event/2528?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Strong earnings haven't been able to buoy U.S. stocks with investors rattled by tariff rhetoric amid President Trump's push to acquire Greenland. Johnson & Johnson on deck today.Important DisclosuresThis material is intended for general informational purposes only. This should not be considered an individualized recommendation or personalized investment advice. The investment strategies mentioned may not be suitable for everyone. Each investor needs to review an investment strategy for his or her own particular situation before making any investment decisions.The Schwab Center for Financial Research is a division of Charles Schwab & Co., Inc.All names and market data shown above are for illustrative purposes only and are not a recommendation, offer to sell, or a solicitation of an offer to buy any security. Supporting documentation for any claims or statistical information is available upon request.Past performance is no guarantee of future results.Diversification and rebalancing strategies do not ensure a profit and do not protect against losses in declining markets.Indexes are unmanaged, do not incur management fees, costs, and expenses and cannot be invested in directly. For more information on indexes, please see schwab.com/indexdefinitions.The policy analysis provided by the Charles Schwab & Co., Inc., does not constitute and should not be interpreted as an endorsement of any political party.Fixed income securities are subject to increased loss of principal during periods of rising interest rates. Fixed income investments are subject to various other risks including changes in credit quality, market valuations, liquidity, prepayments, early redemption, corporate events, tax ramifications, and other factors.All expressions of opinion are subject to change without notice in reaction to shifting market, economic or political conditions. Data contained herein from third party providers is obtained from what are considered reliable sources. However, its accuracy, completeness or reliability cannot be guaranteed.Investing involves risk, including loss of principal, and for some products and strategies, loss of more than your initial investment.Digital currencies [such as bitcoin] are highly volatile and not backed by any central bank or government. Digital currencies lack many of the regulations and consumer protections that legal-tender currencies and regulated securities have. Due to the high level of risk, investors should view digital currencies as a purely speculative instrument.Cryptocurrency-related products carry a substantial level of risk and are not suitable for all investors. Investments in cryptocurrencies are relatively new, highly speculative, and may be subject to extreme price volatility, illiquidity, and increased risk of loss, including your entire investment in the fund. Spot markets on which cryptocurrencies trade are relatively new and largely unregulated, and therefore, may be more exposed to fraud and security breaches than established, regulated exchanges for other financial assets or instruments. Some cryptocurrency-related products use futures contracts to attempt to duplicate the performance of an investment in cryptocurrency, which may result in unpredictable pricing, higher transaction costs, and performance that fails to track the price of the reference cryptocurrency as intended. Please read more about risks of trading cryptocurrency futures here.The Schwab Center for Financial Research is a division of Charles Schwab & Co., Inc.Apple Podcasts and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries.Google Podcasts and the Google Podcasts logo are trademarks of Google LLC.Spotify and the Spotify logo are registered trademarks of Spotify AB.(0131-0126) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This Day in Legal History: Nixon Aides ConvictedOn January 21, 1975, three of Richard Nixon's closest aides—H.R. Haldeman, John Ehrlichman, and former Attorney General John Mitchell—were convicted for their roles in the Watergate cover-up. The charges? Conspiracy, obstruction of justice, and perjury. These convictions weren't just about punishing political wrongdoing; they were the direct legal aftermath of the Supreme Court's ruling in United States v. Nixon six months earlier. That decision famously held that executive privilege—long seen as a near-impenetrable shield—does not extend to cover-ups and criminal conduct. The message was as clear as it was historic: even the most powerful figures in government are not beyond the reach of the law.The Watergate trials became a masterclass in the tension between power and accountability. These weren't fringe operatives—they were the President's top men, brought down not by partisan maneuvering but by due process. In convicting them, the courts affirmed a fundamental principle: constitutional protections are not carte blanche for corruption. That principle has since been tested repeatedly, often invoked but rarely with the same clarity.While Nixon himself was pardoned by Gerald Ford, his aides faced real legal consequences. And in doing so, they served as a sobering example of what happens when loyalty to power eclipses loyalty to the law.On January 24, the U.S. Supreme Court will hear arguments in a high-stakes case involving President Donald Trump's attempt to fire Federal Reserve Governor Lisa Cook—an unprecedented move that could reshape the legal boundaries of central bank independence. Trump is challenging a lower court ruling that barred him from removing Cook while her legal challenge continues. At issue is whether a president can dismiss a Fed governor without due process, despite the Federal Reserve Act's “for cause” removal standard, which lacks clear definition.Cook, the first Black woman appointed to the Fed's board (by President Biden in 2022), argues Trump's push is politically motivated, tied to disagreements over monetary policy. Trump cited past mortgage fraud allegations—which Cook denies—as grounds for her removal, but a district court found those likely insufficient and in violation of her Fifth Amendment rights. The D.C. Circuit declined to stay that ruling.The case has major implications: no president has ever tried to fire a Fed governor, and the Court's decision could determine how insulated the central bank remains from political interference. It also arrives amid broader questions about the scope of presidential control over independent agencies—and a criminal probe into Fed Chair Jerome Powell, which many see as part of the same pressure campaign.By way of brief background, a Federal Reserve governor is a member of the Board of Governors of the Federal Reserve System, the central banking authority of the United States. The Board is composed of seven governors, each appointed by the President and confirmed by the Senate to serve staggered 14-year terms. These governors play a critical role in shaping U.S. monetary policy, overseeing the operations of the Federal Reserve Banks, and regulating certain financial institutions. Their primary responsibilities include setting the discount rate, influencing the federal funds rate (the interest rate banks charge each other for overnight loans), and voting on key decisions made by the Federal Open Market Committee (FOMC)—the body that manages the nation's money supply and interest rate targets.Importantly, Fed governors are designed to be insulated from political pressure to preserve the central bank's independence. That's why they can only be removed by the president “for cause”—a vague legal standard that has rarely, if ever, been tested. This structural independence is meant to prevent short-term political interests from influencing decisions that have long-term economic consequences, such as controlling inflation, stabilizing employment, or responding to financial crises. While their work often operates behind the scenes, the policies they help shape impact virtually every corner of the U.S. economy—from mortgage rates to job growth to the value of the dollar.US Supreme Court considers Trump's bid to fire Fed's Lisa Cook | ReutersA court-appointed special master has recommended that women suing Johnson & Johnson over claims its talc-based products caused ovarian cancer should be allowed to present expert testimony supporting that link in upcoming trials. Retired Judge Freda Wolfson found that the plaintiffs' experts used reliable methods and cited statistically significant studies connecting genital talc use to ovarian cancer. The recommendation—part of a sprawling litigation involving over 67,500 cases—moves the lawsuits closer to federal trial, possibly later this year.Wolfson also allowed J&J's experts to present rebuttal testimony, but excluded certain plaintiff theories, such as talc migration via inhalation or links to fragrance chemicals and heavy metals. J&J criticized the ruling and plans to challenge it, arguing that the scientific evidence wasn't rigorously vetted.The litigation has dragged on for years, complicated by failed bankruptcy attempts by J&J to shield itself from liability. While the company denies its talc contains asbestos or causes cancer, prior jury verdicts have yielded multi-billion-dollar awards for plaintiffs, though some have been overturned. The case could become a major bellwether for corporate liability and the legal standard for expert scientific evidence in mass torts.Experts can testify about suspected J&J talc products' cancer link, special master recommends | ReutersLindsey Halligan, a Trump-aligned prosecutor and former personal attorney to the president, is leaving her post at the U.S. Justice Department after a federal judge sharply rebuked her for continuing to act as U.S. Attorney for the Eastern District of Virginia beyond her legally allowed interim term. Appointed without Senate confirmation, Halligan's authority expired after 120 days, yet she continued using the title—prompting Judge David Novak to call her conduct a “charade” and warn of potential disciplinary action.Halligan had led politically charged investigations targeting Trump adversaries like former FBI Director James Comey and New York Attorney General Letitia James, though those cases were dismissed due to questions over her legitimacy. The Justice Department is appealing those rulings, but the controversy has sparked internal tension, with Novak criticizing the DOJ's recent filings as inflammatory and unprofessional.Her departure follows Senate Democrats' refusal to advance her formal nomination, citing the “blue slip” tradition that allows home-state senators to block nominees. Attorney General Pam Bondi blamed Democrats for obstructing Halligan's tenure, while Trump allies hinted at retaliation if the court names a replacement. The episode underscores ongoing friction between the judiciary, the Justice Department, and Trump's efforts to assert political control over federal prosecutions.After judge's rebuke, Trump ally Halligan to leave US Justice Department | ReutersA Massachusetts judge has ruled that Kalshi, a New York-based prediction market platform, cannot offer sports betting services in the state without a proper gambling license. The decision comes after Attorney General Andrea Campbell sued Kalshi, arguing that it was illegally offering unlicensed sports wagers to residents, including users as young as 18. Judge Christopher Barry-Smith agreed, stating that state oversight of sports betting protects public health and financial interests.Kalshi, which allows users to bet on outcomes of events like sports, politics, and the economy, claimed that its operations fall under the exclusive jurisdiction of the U.S. Commodity Futures Trading Commission (CFTC), due to its status as a registered contract market. The judge rejected that argument, ruling that federal oversight of financial instruments does not override state authority to regulate gambling.Kalshi plans to appeal the injunction, which could be finalized following a hearing. This marks the first court-ordered halt of Kalshi's operations in a state, though it faces similar legal challenges elsewhere. The case underscores growing friction between emerging event-based financial markets and traditional gambling laws.Kalshi cannot operate sports-prediction market in Massachusetts, judge rules | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ARY865. CME/MOC/AAPA/IPCE credit will be available until January 18, 2027.Elevating NMIBC Care: Putting the Latest Innovations for Intravesical Therapies Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ARY865. CME/MOC/AAPA/IPCE credit will be available until January 18, 2027.Elevating NMIBC Care: Putting the Latest Innovations for Intravesical Therapies Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ARY865. CME/MOC/AAPA/IPCE credit will be available until January 18, 2027.Elevating NMIBC Care: Putting the Latest Innovations for Intravesical Therapies Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ARY865. CME/MOC/AAPA/IPCE credit will be available until January 18, 2027.Elevating NMIBC Care: Putting the Latest Innovations for Intravesical Therapies Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

Tallulah Le Merle is an AI investor, advisor, and speaker. She is a Partner at Fifth Era, where she leads the firm's AI strategy. Fifth Era now manages eight investment vehicles with exposure to more than 80 unicorns through fund-of-funds and co-investments. She began her career as a management consultant advising FTSE 100 companies (Johnson & Johnson, Mars, HSBC, Unilever, etc.) on digital and data transformation - including AI strategy back when it was still largely machine learning and big data. She later served as a fractional COO for AI scale-ups, working directly with founders at the heart of the ecosystem. Tallulah speaks frequently on the future of AI and investing at global conferences and panels, often with a lens on the humanity side of the technology equation, and hope in the age of AI. She also hosts Fresh AI, the world's first fully AI-generated daily news podcast on artificial intelligence.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BQU865. CME/MOC/AAPA/IPCE credit will be available until January 2, 2027.Innovative Approaches in Prostate Cancer: Bridging Genomics and Patient-Centric Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Johnson & Johnson, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BQU865. CME/MOC/AAPA/IPCE credit will be available until January 2, 2027.Innovative Approaches in Prostate Cancer: Bridging Genomics and Patient-Centric Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Johnson & Johnson, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BQU865. CME/MOC/AAPA/IPCE credit will be available until January 2, 2027.Innovative Approaches in Prostate Cancer: Bridging Genomics and Patient-Centric Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Johnson & Johnson, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BQU865. CME/MOC/AAPA/IPCE credit will be available until January 2, 2027.Innovative Approaches in Prostate Cancer: Bridging Genomics and Patient-Centric Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Johnson & Johnson, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Re-Release: On this Live Greatly podcast episode, Kristel Bauer sits down with the Founder and CEO of Change Enthusiasm Global, Cassandra Worthy to discuss how to thrive amid change.  Tune in now!  Key Takeaways From This Episode: How to thrive amid change  How emotions can help us navigate change  A mindset shift around change How leaders can help their team's navigate change  A look into Cassandra's journey around change About Cassandra Worthy: Cassandra Worthy is the world's leading expert on Change Enthusiasm®.  Recently named one of the world's Top 50 keynote speakers, she is lighting the world on fire with her refreshingly unique take on not just 'managing' but growing through change.  Through her Leadership Development and consulting company, Change Enthusiasm Global, she is sharing this revolutionary approach for not only embracing change but using it to propel you to heights you never imagined with thousands all over the world.  She is trusted by clients around the globe including Johnson & Johnson, Bank of America, UnitedHealthcare, Google, Microsoft, and Cisco. After spending nearly 15 years working as an executive within both Procter & Gamble and Berkshire Hathaway thriving through some of the biggest acquisitions ever recorded in the consumer packaged goods industry, Cassandra decided to cultivate the mindset and tools she practiced to grow through these disruptions in a way that inspires, invigorates, and motivates others to grow through their change challenges. She's the author of the bestselling  book 'Change Enthusiasm: How to Harness the Power of Emotion for Leadership and Success' a Next Big Idea Club nominee. Connect with Cassandra Worthy: Website: https://cassandraworthy.com/  Become a Certified Change Enthusiast™ Practitioner:  go.changeenthusiasmglobal.com/growth-accelerator LinkedIn: https://www.linkedin.com/in/cassandra-worthy-802ab623/  Instagram: https://www.instagram.com/cassandra_worthy_speaker/  Facebook: https://www.facebook.com/wearechangeenthusiasts/  Youtube: https://www.youtube.com/channel/UCRSgcTNQnQPCTF_0ydJdZvw  About the Host of the Live Greatly podcast, Kristel Bauer: Kristel Bauer is a corporate wellness and performance expert, keynote speaker and TEDx speaker supporting organizations and individuals on their journeys for more happiness and success. She is the author of Work-Life Tango: Finding Happiness, Harmony, and Peak Performance Wherever You Work (John Murray Business November 19, 2024). With Kristel's healthcare background, she provides data driven actionable strategies to leverage happiness and high-power habits to drive growth mindsets, peak performance, profitability, well-being and a culture of excellence. Kristel's keynotes provide insights to "Live Greatly" while promoting leadership development and team building.   Kristel is the creator and host of her global top self-improvement podcast, Live Greatly. She is a contributing writer for Entrepreneur, and she is an influencer in the business and wellness space having been recognized as a Top 10 Social Media Influencer of 2021 in Forbes. As an Integrative Medicine Fellow & Physician Assistant having practiced clinically in Integrative Psychiatry, Kristel has a unique perspective into attaining a mindset for more happiness and success. Kristel has presented to groups from the American Gas Association, Bank of America, bp, Commercial Metals Company, General Mills, Northwestern University, Santander Bank and many more. Kristel has been featured in Forbes, Forest & Bluff Magazine, Authority Magazine & Podcast Magazine and she has appeared on ABC 7 Chicago, WGN Daytime Chicago, Fox 4's WDAF-TV's Great Day KC, and Ticker News. Kristel lives in the Fort Lauderdale, Florida area and she can be booked for speaking engagements worldwide. To Book Kristel as a speaker for your next event, click here. Website: www.livegreatly.co  Follow Kristel Bauer on: Instagram: @livegreatly_co  LinkedIn: Kristel Bauer Twitter: @livegreatly_co Facebook: @livegreatly.co Youtube: Live Greatly, Kristel Bauer To Watch Kristel Bauer's TEDx talk of Redefining Work/Life Balance in a COVID-19 World click here. Click HERE to check out Kristel's corporate wellness and leadership blog Click HERE to check out Kristel's Travel and Wellness Blog Disclaimer: The contents of this podcast are intended for informational and educational purposes only. Always seek the guidance of your physician for any recommendations specific to you or for any questions regarding your specific health, your sleep patterns changes to diet and exercise, or any medical conditions.  Always consult your physician before starting any supplements or new lifestyle programs. All information, views and statements shared on the Live Greatly podcast are purely the opinions of the authors, and are not medical advice or treatment recommendations.  They have not been evaluated by the food and drug administration.  Opinions of guests are their own and Kristel Bauer & this podcast does not endorse or accept responsibility for statements made by guests.  Neither Kristel Bauer nor this podcast takes responsibility for possible health consequences of a person or persons following the information in this educational content.  Always consult your physician for recommendations specific to you.

Patrick Ropella is the Founder and Chairman of Ropella 360, a global executive search and advisory firm specializing in connecting transformational leaders with private equity and mid-market companies. With over 35 years of experience, he has contributed to the growth of major global corporations such as Dow, General Electric, BASF, Nike, and Johnson & Johnson. As the author of The Right Hire and Pathways to Private Equity Partnerships, Patrick's C-suite and investor insights are featured in hundreds of publications worldwide. His strategic vision and expertise have made him a trusted advisor to leaders across industries. In this episode… The path to extraordinary success often starts in unexpected places — from humble beginnings to high-stakes boardrooms. Some people manage to rise without the usual credentials, building influence, trust, and transformative relationships along the way. What enables someone to become a connector who impacts leaders, industries, and entire organizations? According to Patrick Ropella, a renowned leadership strategist, the real advantage comes from mastering human connection rather than relying on traditional qualifications. He highlights how deep listening, specialization, and long-term trust outperform transactional sales and recruiting. This approach creates lasting impact by aligning the right leaders with the right missions. Over decades, he developed a system for identifying A-players, ensuring cultural fit, and supporting leadership transformation across complex industries. His stories — from helping global brands innovate to supporting frontier-technology teams — show how clarity, accountability, and relationship-building shape high-performance outcomes. In this episode of the Inspired Insider Podcast, Dr. Jeremy Weisz sits down with Patrick Ropella, Founder and Chairman of Ropella 360, to discuss building elite teams through authentic leadership. They explore how to identify A-players, the principles behind his Smart Search System, and what drives lasting transformation in organizations. Patrick also shares insights on trust, communication, and scaling through strong relationships.

On this Live Greatly podcast episode, Kristel Bauer sits down with "Courage Catalyst" Dr. Margie Warrell, six-time bestselling author of The Courage Gap.  Kristel and Margie discuss how to navigate being an insecure overachiever and how to build courage. Tune in now!  Key Takeaways From This Episode: A look into being an insecure overachiever and how to overcome it Tips to build courage within ourselves A look into Dr. Warrell's book, The Courage Gap ABOUT DR. MARGIE WARRELL Dr. Margie Warrell is a six-time bestselling author, leadership advisor, keynote speaker, and "courage catalyst" bringing deep insight into human and organizational behavior to foster braver leadership and better outcomes.  Dr. Warrell has gained profound insights on managing fear, navigating risk, and embracing change since her childhood in rural Australia. Thirty years of living and working around the world—from Papua, New Guinea to Singapore—have provided her with a globally grounded perspective on navigating risk and overcoming the barriers that stifle potential in individuals and organizations. Drawing on her doctoral research and experience in coaching and Fortune 500 consulting, Dr. Warrell is a trusted advisor across private and public sectors, helping to embolden braver leadership and cultivate forward-thinking "cultures of courage" that counter change resistance, foster learning, and accelerate growth. Organizations such as NASA, Dell, Morgan Stanley, SAP, Novartis, the UN Foundation, HP, Google, and Johnson & Johnson have sought her expertise.  Author of the new book, The Courage Gap, Dr. Warrell is renowned for her ability to bridge the "head and heart" as a writer and speaker. She has also co-authored two other books with Stephen Covey, Ken Blanchard, and Jack Canfield. Her interviews with leaders and luminaries—including Bill Marriott, Richard Branson, and Amy Edmondson of Harvard Business School—inform her thought leadership, which she shares through her global top 1.5% podcast, Live Brave, Forbes column, and leading media outlets such as CNN, Bloomberg, and the WSJ. Dr. Warrell's commitment to "braver leadership for a better world" extends to advising US Congressional Chiefs, McCain Global Fellows, and emerging female leaders in burgeoning democracies. A passionate advocate for women in leadership, she has served on numerous government roundtables, co-led Korn Ferry's Power of All initiative to advance more women to C-suite and board tables, and been Senior Partner in their CEO & Leadership Institute. Connect with Dr. Warrell Order Dr. Warrell's book: https://a.co/d/81cuf2F  Website: https://margiewarrell.com/  Linkedin: https://www.linkedin.com/in/margiewarrell/  Instagram: https://www.instagram.com/margiewarrell/  About the Host of the Live Greatly podcast, Kristel Bauer: Kristel Bauer is a corporate wellness and performance expert, keynote speaker and TEDx speaker supporting organizations and individuals on their journeys for more happiness and success. She is the author of Work-Life Tango: Finding Happiness, Harmony, and Peak Performance Wherever You Work (John Murray Business November 19, 2024). With Kristel's healthcare background, she provides data driven actionable strategies to leverage happiness and high-power habits to drive growth mindsets, peak performance, profitability, well-being and a culture of excellence. Kristel's keynotes provide insights to "Live Greatly" while promoting leadership development and team building.   Kristel is the creator and host of her global top self-improvement podcast, Live Greatly. She is a contributing writer for Entrepreneur, and she is an influencer in the business and wellness space having been recognized as a Top 10 Social Media Influencer of 2021 in Forbes. As an Integrative Medicine Fellow & Physician Assistant having practiced clinically in Integrative Psychiatry, Kristel has a unique perspective into attaining a mindset for more happiness and success. Kristel has presented to groups from the American Gas Association, Bank of America, bp, Commercial Metals Company, General Mills, Northwestern University, Santander Bank and many more. Kristel has been featured in Forbes, Forest & Bluff Magazine, Authority Magazine & Podcast Magazine and she has appeared on ABC 7 Chicago, WGN Daytime Chicago, Fox 4's WDAF-TV's Great Day KC, and Ticker News. Kristel lives in the Fort Lauderdale, Florida area and she can be booked for speaking engagements worldwide. To Book Kristel as a speaker for your next event, click here. Website: www.livegreatly.co  Follow Kristel Bauer on: Instagram: @livegreatly_co  LinkedIn: Kristel Bauer Twitter: @livegreatly_co Facebook: @livegreatly.co Youtube: Live Greatly, Kristel Bauer To Watch Kristel Bauer's TEDx talk of Redefining Work/Life Balance in a COVID-19 World click here. Click HERE to check out Kristel's corporate wellness and leadership blog Click HERE to check out Kristel's Travel and Wellness Blog Disclaimer: The contents of this podcast are intended for informational and educational purposes only. Always seek the guidance of your physician for any recommendations specific to you or for any questions regarding your specific health, your sleep patterns changes to diet and exercise, or any medical conditions.  Always consult your physician before starting any supplements or new lifestyle programs. All information, views and statements shared on the Live Greatly podcast are purely the opinions of the authors, and are not medical advice or treatment recommendations.  They have not been evaluated by the food and drug administration.  Opinions of guests are their own and Kristel Bauer & this podcast does not endorse or accept responsibility for statements made by guests.  Neither Kristel Bauer nor this podcast takes responsibility for possible health consequences of a person or persons following the information in this educational content.  Always consult your physician for recommendations specific to you.